-

Former Top Altria Exec Takes the Reigns at Respira Technologies: Brian Quigley Is Appointed CEO

LOS ANGELES--(BUSINESS WIRE)--Respira Technologies, Inc.—a clinical-stage company developing inhaled therapeutics for smoking cessation and drug delivery technologies to treat cardiopulmonary diseases—has appointed former Altria Group executive and current Respira COO Brian Quigley as its new Chief Executive Officer. Respira’s founder, Mario Danek, will transition to the role of Chief Technology Officer.

Quigley spent 16 years at Altria Group, with seven years as President & CEO at Altria’s Smokeless and Innovative Products/Vapor Businesses. Quigley has been an active investor in both the cannabis and alcohol spaces and sits on the boards of Mustgrow Biologics and Belle Isle Craft Spirits.

With Respira in the midst of securing financing for clinical trials, Danek made a significant change to the structure of the company’s leadership team. Quigley’s background as a successful business leader and Fortune 150 CEO in the space will help drive Respira to its next phase as it advances to an IND submission to begin human clinical trials. This transition will enable Danek to focus on the technology behind Respira, concentrating on inventing and refining its innovative inhalation device across multiple potential indication areas and target markets.

Respira, where Quigley spent the past two years as COO, is a California venture-backed health tech company focused on commercializing proprietary inhalation device technologies to improve patient outcomes. The company is currently engaged with FDA CEDR to pursue a combination product authorization as the first inhalable prescription smoking cessation therapy.

About Respira Technologies, Inc.

Respira, based in Los Angeles, was founded by Mario Danek in 2018 to build cutting-edge drug delivery platforms that improve patient outcomes through superior device technologies.

The company’s key product, the RespiRx™, is the first orientation-agnostic, portable VMN device that effectively operates in any position held by the patient. Respira sees significant opportunity to utilize its drug delivery technologies to improve the treatment of Asthma, COPD, Vaccine Delivery, Pain Management, and several generic as well as select investigational new drugs with safe and effective inhalable drug delivery mechanisms that only the RespiRx™ can deliver.

Respira is backed by venture firms Blue Ledge Capital, DG Ventures, Evolution VC Partners, and Poseidon Asset Management.

Contacts

Investor Relations:
Respira Technologies, Inc.
IR@Respiratechnologies.com

Media Relations:
Richard Laermer
RLM PR
212-741-5106 X 216
Respira@RLMpr.com

Industry:

Respira Technologies, Inc.

Release Versions
English

Contacts

Investor Relations:
Respira Technologies, Inc.
IR@Respiratechnologies.com

Media Relations:
Richard Laermer
RLM PR
212-741-5106 X 216
Respira@RLMpr.com

More News From Respira Technologies, Inc.

Qnovia, Inc. Announces the Appointment of Four New Members to its Scientific Advisory Board

RICHMOND, Va.--(BUSINESS WIRE)--Qnovia, Inc., a pharmaceutical company developing inhaled therapeutics across a variety of indication areas leveraging its proprietary inhaled drug delivery platform, the RespiRxTM, today announced the appointment of four new members to its Scientific Advisory Board (SAB). The new members include Neal Benowitz, MD, Professor at University of California at San Francisco, Ian M. Fearon, PhD, independent consultant, Darla E. Kendzor, PhD, Professor at University of...

Qnovia, Inc. announces positive results from first-in-human pharmacokinetic and safety study of lead asset QN-01, a prescription inhaled smoking cessation therapy

RICHMOND, Va.--(BUSINESS WIRE)--Qnovia, Inc., a pharma company developing inhaled therapeutics across a variety of indication areas leveraging its proprietary inhaled drug delivery platform, the RespiRxTM, today announced positive results from its first in-human study of QN-01, the company’s lead asset. QN-01 is an inhaled smoking cessation therapy that is currently being evaluated in the U.S. under FDA’s Center for Drug Evaluation and Research (CDER) and in the U.K. by the Medicines and Health...

Qnovia Enters Collaboration with University of Virginia to Advance Inhaled Drug Candidates for Treating Infectious Diseases

RICHMOND, Va.--(BUSINESS WIRE)--Qnovia, Inc., a pharma company developing inhaled therapeutics across a variety of indication areas, today announced it has entered into a drug development collaboration with the University of Virginia (UVA) to advance novel inhaled-drug candidates for treating bacterial infections in the lungs. Qnovia will work with UVA School of Medicine investigators Dr. Molly Hughes and Dr. Matthew Crawford to combine Qnovia’s RespiRxTM inhaled drug delivery platform and UVA’...
Back to Newsroom